Literature DB >> 22013036

Transcriptional repression and RNA silencing act synergistically to demonstrate the function of the eleventh component of the vaccinia virus entry-fusion complex.

Cindy L Wolfe1, Suany Ojeda, Bernard Moss.   

Abstract

Poxviruses have an elaborate system for infecting cells comprising several proteins for attachment and a larger number dedicated to membrane fusion and entry. Thus far, 11 proteins have been identified as components of the vaccinia virus (VACV) entry-fusion complex (EFC), and 10 of these proteins have been shown to be required for entry. J5, the remaining functionally uncharacterized component of the complex, is conserved in all poxviruses, has a predicted C-terminal transmembrane domain, and is an N-terminally truncated paralog of two other EFC proteins. To determine the role of J5, we constructed a mutant that inducibly regulates J5 transcription. Although the virus yield was reduced only about 80% without inducer, the inability to isolate a J5 deletion mutant suggested an essential function. To enhance stringency, we employed RNA silencing alone and together with transcriptional repression of the inducible mutant. The yield of infectious virus was reduced 4- to 5-fold by repression, 2-fold by silencing, and 60-fold by the combination of the two. Virus particles made under the latter conditions appeared to contain a full complement of proteins excluding J5 but had very low infectivity. Further studies indicated that after binding to cells, J5-deficient virions had a defect in core entry and an inability to induce syncytium formation. In addition, we confirmed that J5 is associated with the EFC by affinity purification. These data indicate that J5 is a functional component of the EFC and highlights the advantage of combining transcriptional repression and RNA silencing for stringent reduction of gene expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013036      PMCID: PMC3255872          DOI: 10.1128/JVI.05935-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing.

Authors:  Zhilong Yang; Daniel P Bruno; Craig A Martens; Stephen F Porcella; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane.

Authors:  R W Doms; R Blumenthal; B Moss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  Participation of vaccinia virus l2 protein in the formation of crescent membranes and immature virions.

Authors:  Liliana Maruri-Avidal; Arban Domi; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

5.  Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein.

Authors:  S C Gong; C F Lai; M Esteban
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

6.  Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.

Authors:  W A Alexander; B Moss; T R Fuerst
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Interaction between the G3 and L5 proteins of the vaccinia virus entry-fusion complex.

Authors:  Cindy L Wolfe; Bernard Moss
Journal:  Virology       Date:  2011-02-04       Impact factor: 3.616

8.  A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.

Authors:  E J Wolffe; S Vijaya; B Moss
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

9.  Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.

Authors:  P S Satheshkumar; Bernard Moss
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

10.  Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene.

Authors:  Tatiana G Senkevich; Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  6 in total

1.  Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH.

Authors:  Shu-Jung Chang; Ao-Chun Shih; Yin-Liang Tang; Wen Chang
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Authors:  Chwan Hong Foo; J Charles Whitbeck; Manuel Ponce-de-León; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

3.  Sequence-divergent chordopoxvirus homologs of the o3 protein maintain functional interactions with components of the vaccinia virus entry-fusion complex.

Authors:  P S Satheshkumar; Bernard Moss
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

4.  Integrin β1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.

Authors:  Roza Izmailyan; Jye-Chian Hsao; Che-Sheng Chung; Chein-Hung Chen; Paul Wei-Che Hsu; Chung-Lin Liao; Wen Chang
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

5.  Orthopoxvirus species and strain differences in cell entry.

Authors:  Zain Bengali; P S Satheshkumar; Bernard Moss
Journal:  Virology       Date:  2012-09-20       Impact factor: 3.616

Review 6.  Poxvirus cell entry: how many proteins does it take?

Authors:  Bernard Moss
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.